APOGEN Drug Patent Profile
✉ Email this page to a colleague
When do Apogen patents expire, and when can generic versions of Apogen launch?
Apogen is a drug marketed by King Pharms and is included in one NDA.
The generic ingredient in APOGEN is gentamicin sulfate. There is one drug master file entry for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the gentamicin sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Apogen
A generic version of APOGEN was approved as gentamicin sulfate by SANDOZ on December 31st, 1969.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for APOGEN?
- What are the global sales for APOGEN?
- What is Average Wholesale Price for APOGEN?
Summary for APOGEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 34 |
| DailyMed Link: | APOGEN at DailyMed |
US Patents and Regulatory Information for APOGEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| King Pharms | APOGEN | gentamicin sulfate | INJECTABLE;INJECTION | 062289-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| King Pharms | APOGEN | gentamicin sulfate | INJECTABLE;INJECTION | 062289-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
